From: Asthma and COPD in cystic fibrosis intron-8 5T carriers. A population-based study
Poly-T | Expected exon-9 skipping, % | F508del heterozygosity | n | Incidence n/10000 person-years | P-value* | Unadjusted HR (95%CI) | Adjusted† HR (95%CI) | 90% power‡ HR |
---|---|---|---|---|---|---|---|---|
9T/9T | 7 | 83 | 40 | 0.10 | 1.8 (0.89–3.6) | 1.7 (0.85–3.5) | 2.3 | |
7T/9T | 13 | 1540 | 21 | 0.70 | 0.95 (0.75–1.2) | 0.99 (0.78–1.3) | 1.3 | |
7T/7T | 18 | 6905 | 22 | - | 1.0 | 1.0 | - | |
6T/7T | ≥18 | 4 | 105 | 0.08 | 4.9 (0.69–35) | 7.6 (1.0–55) | 11 | |
5T/9T | 43 | 40 | 21 | 0.90 | 0.92 (0.23–3.7) | 0.75 (0.19–3.0) | 3.0 | |
5T/7T | 48 | 308 | 11 | 0.03 | 0.47 (0.23–0.95) | 0.49 (0.23–1.0) | 1.6 | |
5T/5T | 78 | 2 | 0 | 0.73 | - | - | 19 | |
9T/9T | - | yes | 23 | 0 | 0.25 | - | - | 3.8 |
7T/9T | - | yes | 217 | 25 | 0.73 | 1.1 (0.63–1.9) | 1.1 (0.62–1.9) | 1.7 |
7T/7T | - | yes | 5 | 0 | 0.59 | - | 9.7 | |
5T/9T | - | yes | 4 | 0 | 0.63 | - | - | 11 |